Table 1. Baseline characteristics of the patient cohort.
PORTELA, Joana, et al. Development and disease-dependent dynamics of spermatogonial subpopulations in human testicular tissues. Journal of clinical medicine, 2020, 9. Jg., Nr. 1, S. 224.
Publication: https://doi.org/10.3390/jcm9010224
Description
According to diagnosis, treatment received and occurrence of any testicular pathology, patients were divided into two groups: NT: untreated cancer patients without any preexisting (congenital) risk factors for impaired testicular function; AT: patients with potentially affected tissues by disease or treatment. The average age of the patients in NT and AT group is not significantly different (9.1 and 9.5 years, respectively).* Patients with low spermatogonial counts and a patient with germ cell neoplasia in situ (AT21) were excluded from further analysis. Testicular volumes were determined by palpation using a Prader orchidometer and additionally confirmed by ultrasonography. # Indicates one patient for whom testicular volume was only determined by Prader orchidometer.
Disclaimer
The publication Development and Disease-Dependent Dynamics of Spermatogonial Subpopulations in Human Testicular Tissues by Joana M. D. Portela, Laura Heckmann, Joachim Wistuba, Andrea Sansone, Ans M. M. van Pelt, Sabine Kliesch, Stefan Schlatt and Nina Neuhaus is published under an open access license: https://creativecommons.org/licenses/by/4.0/. Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Curation by the MFGA team
Pie chart of selected column
Table
PatientNumber | Diagnosis(treatmentBeforeTestisBiopsy) | Group | Age(years) | TestisVolume(ml) |
---|---|---|---|---|
NT1 | Ependymoma | NT | 2.5 | 1.5 |
NT2 * | Acute myeloid leukemia | NT | 3 | 0.33 |
NT3 | Hodgkins lymphoma | NT | 5 | 1 |
NT4 | Hodgkins lymphoma | NT | 6 | 1 |
NT5 | Rhabdomyosarcoma | NT | 7 | 0.83 |
NT6 | Ewing sarcoma | NT | 8 | 0.40 |
NT7 | Intracranial germ cell tumor | NT | 9 | 1.3 |
NT8 | Rhabdomyosarcoma | NT | 10.5 | 1.8 |
NT9 | Hodgkins lymphoma | NT | 11 | 1 |
NT10 | Osteosarcoma | NT | 11 | 2 |
NT11 | Hodgkins lymphoma | NT | 13 | 1 |
NT12# | Sarcoma | NT | 14 | 8 |
NT13 | Lymphoma | NT | 14 | 19 |
NT14 | Non-Hodgkins lymphoma | NT | 14 | 9 |
AT1 | Immunodeficiency (chemotherapy) | AT | 0.42 | |
AT2 | Thalassemia | AT | 2 | 0.3 |
AT3 | Testicular tumor; pubertas praecox | AT | 3 | 8 |
AT4 | Immunodeficiency | AT | 4 | 0.4 |
AT5 | Leukemia (allogeneic bone marrow transplantation) | AT | 6 | |
AT6 | Sickle cell disease (hydroxyurea) | AT | 6 | 1 |
AT7 | Myelodysplastic syndrome | AT | 7 | 1 |
AT8 * | Sickle cell disease; cryptorchid testes | AT | 7 | 1 |
AT9 | Sickle cell disease (hydroxyurea) | AT | 8 | 0.3 |
AT10 | Myelodysplastic syndrome | AT | 9 | 1 |
AT11 | Thalassemia major | AT | 10 | 1 |
AT12 | Hodgkins lymphoma; cryptorchid testes | AT | 10 | 1 |
AT13 | Sickle cell disease (hydroxyurea) | AT | 10 | 2 |
AT14 | Myelodysplastic syndrome | AT | 12 | 1.4 |
AT15 * | Cryptorchid testes; hypogonadism | AT | 12 | - |
AT16 | Thalassemia major | AT | 12 | 1 |
AT17 | Leukemia (chemotherapy) | AT | 13 | 8 |
AT18 * | Cryptorchid testes | AT | 14 | 6 |
AT19 | Lymphoma (chemotherapy) | AT | 15 | 6 |
AT20 | Leukemia; cryptorchid testes (chemotherapies) | AT | 16 | 5 |
AT21 * | Testicular tumor; cryptorchid testes | AT | 16 | 3 |
AT22 | Cryptorchid testes | AT | 17 | 3 |